文献速递类风湿关节炎

生物制剂降低类风湿关节炎患者全膝与全髋置换风险

Effects of biologics on reducing the risks of total knee replacement and total hip replacement in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项基于2000-2013年台湾全民健康保险理赔数据库的回顾性全国研究,比较了生物制剂队列与年龄性别匹配的csDMARD队列的TKR和THR风险。结果显示生物制剂队列TKR和THR发生率显著更低,校正混杂后规律使用bDMARD(平均剂量>0.95 defined daily dose/day)者TKR风险aHR 0.55(95%CI 0.38,0.81)、THR风险aHR 0.63(95%CI 0.40,0.98)。

要点

  • 生物制剂队列TKR发生率11.73 vs 16.33/1000人年,THR发生率7.09 vs 9.16/1000人年,均P<0.001。
  • 规律使用bDMARD者TKR风险aHR 0.55(95%CI 0.38,0.81),THR风险aHR 0.63(95%CI 0.40,0.98)。
  • 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者TKR和THR风险显著更高。

核心结论

  • 与csDMARD队列相比,bDMARD队列中低至中等剂量亚组的TKR和THR风险与csDMARD队列相同,而规律使用bDMARD者风险显著更低。

研究设计与样本

  • 回顾性全国性研究,使用2000-2013年理赔型全民健康保险数据库,生物制剂队列与年龄性别匹配的csDMARD队列比较。

主要发现

  • 生物制剂队列TKR发生率显著更低(11.73 vs 16.33/1000人年,P<0.001)。
  • 生物制剂队列THR发生率显著更低(7.09 vs 9.16/1000人年,P<0.001)。
  • 校正混杂后,规律bDMARD亚组(平均剂量>0.95 defined daily dose/day)TKR风险aHR 0.55(95%CI 0.38,0.81),THR风险aHR 0.63(95%CI 0.40,0.98)。

关键数值与推荐

  • 规律bDMARD使用定义为平均剂量>0.95 defined daily dose/day。
  • 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者TKR和THR风险显著更高。

临床怎么用

  • 对于难治性RA患者,规律使用bDMARD可能降低全膝和全髋置换风险。
  • 未用MTX、使用激素、生物制剂转换及重叠抗磷脂综合征者需关注关节置换风险。

局限性

  • 本研究为回顾性理赔数据库研究,可能存在混杂因素。
  • 生物制剂仅覆盖难治性病例,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: RA damages the joints and increases the risks of total knee replacement (TKR) and total hip replacement (THR). However, the benefits of biologics in preventing TKR or THR remain unclear. METHODS: This retrospective nationwide study used the 2000-2013 claims-based National Health Insurance dataset. Biologics are reimbursed for refractory cases. The risks of TKR and THR in the biologic cohort were compared with those of an age- and sex-matched csDMARD cohort. A multivariate Cox regression model was used to investigate the benefits of bDMARDs for TKR and THR. RESULTS: TKR was performed in 5979 biologic cases and 11 958 matched controls, of which 249 (4.16%) and 871 (7.28%) cases received TKR, respectively. THR was performed in 6245 biologic cases and 12 490 matched controls, of which 159 (2.55%) and 516 (4.13%) cases had THR, respectively. The biologic cohort had significantly lower incidence rates of TKR (11.73 vs 16.33/1000 person-years, P < 0.001) and THR (7.09 vs 9.16/1000 person-years, P < 0.001). After adjustment for confounding factors, the regular bDMARD subgroup (average dose >0.95 defined daily dose/day) had significantly lower risks of TKR (aHR: 0.55, 95% CI: 0.38, 0.81) and THR (aHR: 0.63, 95% CI: 0.40, 0.98). Those without MTX use, with steroid use, with biologic switch, and overlapping antiphospholipid syndrome had significantly higher risks of TKR and THR. CONCLUSIONS: Compared with the csDMARD cohort, the risks of TKR and THR in the bDMARD cohort were the same as those in the low-to-moderate dose subgroups and significantly lower in those with regular bDMARD use.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chang YS, Chen JH, Lin TM, et al. Effects of biologics on reducing the risks of total knee replacement and total hip replacement in rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34534283. doi:10.1093/rheumatology/keab671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。